ContraFect : Q2 2023 Investor Presentation

Corporate Presentation

August 2023

NASDAQ: CFRX

Forward Looking Statements/Disclaimer

This presentation contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believe," "expect," "target", "anticipate," "estimate," "intend," "plan," "proposed", "potential" or similar references to future periods. Examples of forward-looking statements in this presentation include, without limitation, statements made regarding ContraFect Corporation's ("ContraFect") ability to develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic- resistant infections, cited information, clinical trial and pre-clinical study results, data analyses and comparisons, health economic data, safety and efficacy of exebacase, exebacase's value proposition, patent protection, commercial assessments, in vitro and in vivo study results, ContraFect's plans regarding its next IND and extrapolated data. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, proposals, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including ContraFect's need for substantial additional funding, the risks related to the COVID-19 pandemic, the occurrence of any adverse events related to the discovery, development and commercialization of the Company's product candidates such as unfavorable clinical trial results, changes in management, insufficient supplies of drug products, or lack of regulatory approval, risks related to ContraFect's BARDA contract, the unsuccessful attainment or maintenance of patent protection, ContraFect's ability to remain listed on the Nasdaq Stock Exchange or another exchange, litigation risks and other important risks detailed in ContraFect's Quarterly Report on Form 10-Q for the period ended June 30, 2023, and other filings with the Securities and Exchange Commission ("SEC"). Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this presentation is based only on information currently available and speaks only as of the date on which it is made. No representation or warranty is made as to the completeness or accuracy of the information provided in this presentation. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Audiences are cautioned that forward-looking statements or similar information are not guarantees of future performance and, accordingly, are expressly cautioned not to put undue reliance on forward-looking statements or similar information due to the inherent uncertainty therein.

©2023 ContraFect Corporation

Executive Summary

ContraFect

CF-370

Exebacase

Development

• Clinical stage company focused on discovering and developing first-in-class biologic therapies for life-threatening,drug-resistant infectious diseases
• Proprietary technology to develop disruptive anti-infective agents
• First-in-classlysin with broad spectrum activity against Gram-negative pathogens, including Pseudomonas aeruginosa
• Potential for empiric use, covering multi-drug resistant (MDR) strains
• Rapid bactericidal and antibiofilm activity; synergistic activity with broad range of standard-of-care antibiotics to address drug resistance
• First-in-classlysin with potent activity against Staphylococcus aureus, including methicillin-resistantStaphylococcus aureus (MRSA) strains
• Exhibiting long-lasting effect and safe profile in prosthetic joint infection compassionate use cases
• Demonstrated eradication of biofilms in numerous in vitro, ex vivo, and in vivo studies
• ContraFect is advancing its two lysin assets in clinic:
• • CF-370first-in-human Phase 1 anticipated to begin this year, with Phase 2 PoC to evaluate CF-370 in Cystic Fibrosis patients with pulmonary infections
  • Exebacase Phase 1b/2 in patients with prosthetic joint infections has been initiated with first patient dosed in April 2023

3

Resistant Pathogens are Responsible for Numerous Deaths Worldwide

Drug resistance is a global crisis with grim outlook that demands new effective antimicrobials

Current Market Need

Current Drug Resistance Unmet Needs

2 MILLION	700,000
Illnesses diagnosed in the US	Deaths Globally

MRSA	64%
Bigger killer than	Likelihood of death
HIV/AIDS, Parkinson's Disease,	among individuals with
Emphysema, and homicide in the	MRSA vs. those infected with
U.S.	MSSA

Projections by 2050

Projected Global Statistics by 2050

10	$100
MILLION	TRILLION
Deaths Globally	Global costs by 2050

Abbreviations: MRSA: Methicillin-resistantStaphylococcus aureus; MSSA: Methicillin-susceptibleStaphylococcus aureus.	4
Sources: 1. The Review on Antimicrobial Resistance, Chaired by Jim O'Neill, May 2016; 2. Internal estimates.

Resistant Pathogens Represent a Critical Unmet Need

There remains an urgent need for alternatives that circumvent bacterial resistance or suppress resistance to current medicines

Subset of Pathogens Responsible for Antimicrobial Resistance-Related Deaths

• Six pathogens were responsible for 73% of deaths attributable to antimicrobial resistance and 72% of deaths associated with antimicrobial resistance in 2019
• S. aureus and P. aeruginosa vastly contribute to the antimicrobial resistance burden

Three Infection Syndromes Dominate Global Burden

• Lower respiratory and thorax infections, bloodstream infections, and intraabdominal infections accounted for ~78% of deaths attributable to antimicrobial resistance in 2019

Few Novel Options to Treat Resistant Infections

• Only one antibacterial addressing a novel target has been approved since 1990

Deaths by Resistant Pathogen

900,00

0

600,00

0

300,00

0

0

Deaths by Infection Type

2,000,000

1,500,000

1,000,000

500,000

0

Lower	BSI	IAI	UTI	TB	Skin
Respiratory

Abbreviations: BSI: Bloodstream Infection; IAI: Intra-abdominal Infection; UTI: Urinary Tract Infection; TB: Tuberculosis. Sources: 1. The State of Innovation in Antibacterial Therapeutics, Bio,	5
February 2022, excluding agents for C. difficile; 2. Global burden of bacterial antimicrobial resistance in 2019:a systematic analysis, Lancet, January 2022.